Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Current Deferred Revenue (2016 - 2018)

Cardiff Oncology's Current Deferred Revenue history spans 3 years, with the latest figure at $486636.0 for Q4 2018.

  • For Q4 2018, Current Deferred Revenue rose 45.51% year-over-year to $486636.0; the TTM value through Dec 2018 reached $486636.0, up 45.51%, while the annual FY2018 figure was $486636.0, 45.51% up from the prior year.
  • Current Deferred Revenue for Q4 2018 was $486636.0 at Cardiff Oncology, up from $472251.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $486636.0 in Q4 2018 and bottomed at $279710.0 in Q3 2016.
  • The 3-year median for Current Deferred Revenue is $316318.5 (2017), against an average of $341846.1.
  • The largest annual shift saw Current Deferred Revenue grew 6.62% in 2017 before it surged 58.36% in 2018.
  • A 3-year view of Current Deferred Revenue shows it stood at $285246.0 in 2016, then grew by 17.24% to $334424.0 in 2017, then soared by 45.51% to $486636.0 in 2018.
  • Per Business Quant, the three most recent readings for CRDF's Current Deferred Revenue are $486636.0 (Q4 2018), $472251.0 (Q3 2018), and $349565.0 (Q2 2018).